DOCK4 and prostate carcinoma: Elevated miR-33b-3p significantly reduced the metastasis of prostate cancer cells by targeting DOCK4. Moreover, downregulation of miR-33b-3p post bortezomib treatment was associated the insufficient inhibition on prostate cancer cells migration and invasion.